Navigation Links
Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease
Date:5/20/2008

ers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating Cimzia(R) therapy. Exercise caution in prescribing Cimzia(R) for patients identified as carriers of HBV. Patients who are carriers of HBV and require treatment with Cimzia(R) should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, discontinue Cimzia(R) and initiate effective anti-viral therapy with appropriate supportive treatment.

During controlled and open-labeled portions of Cimzia(R) studies of Crohn's disease and other investigational uses, malignancies were observed at a rate (95% confidence interval) of 0.6 (0.4, 0.8) per 100 patient-years among 4,650 Cimzia(R)-treated patients verses a rate of 0.6 (0.2, 1.7) per 100 patient-years among 1,319 placebo-treated patients. The size of the control group and limited duration of the controlled portions of the studies preclude the ability to draw firm conclusions. In studies of Cimzia(R) for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 Cimzia(R)-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. The potential role of TNF blocker therapy in the development of malignancies is not known.

Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following Cimzia(R) administration. If such reactions occur, discontinue further administration of Cimzia(R) and institute appropriate therapy.

Use of TNF blockers, including Cimzia(R), has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, o
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
3. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
4. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
5. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
6. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
7. Gene Therapy Provides Vision to People who Were Nearly Blind
8. Arpida Provides Further Comments on the Pivotal Phase III Trials
9. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
10. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... MINNEAPOLIS , July 23, 2014 ... they have added 14 new vendors so far ... Creekridge,s newest vendors are from both ... mid-size domestic organizations to large, well-known multi-national companies. ... Creekridge,s diversified suite of financing products including: standard ...
(Date:7/23/2014)... South Korea , July 23, 2014  Mezzion ... clinical program to evaluate the use of udenafil to ... for single ventricle heart defects. The clinical program will ... representatives of the Pediatric Heart Network (PHN), a multi-center ... and Blood Institute (NHLBI) of the National Institutes of ...
(Date:7/23/2014)... LONDON , July 23, 2014  Lightlake ... developing addiction treatments based on its expertise in ... an investigational new drug application ("IND") with respect ... Lightlake also announced today that it has received ... Drug Abuse ("NIDA"), part of the National Institutes ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
(Date:7/23/2014)... 2014 In its latest blog post, ... that having family close by during a stay in rehab ... process is successful, is focusing on a topic that is ... addiction-related dialogues: opiate abuse facts. , The Best Drug Rehabilitation ... An overview of opiates, and why they’re considered “the ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The Europe Drilling ... drilling fluid and completion fluid market in Europe with analysis ... market in Europe is estimated to grow from around $1.3 ... CAGR of 6.1%, for the given period. , Browse through ... Market Report, to get an idea of the in-depth analysis ...
(Date:7/23/2014)... 2014 AidJoy is delighted to announce that ... Zen on September 5, 2014 from 7:00 to 11:00 ... are expected to attend this semi-formal event. , "We are ... past six years," says Jess Dennis, Director of Operations and ... on this moment in AidJoy’s history before we launch into ...
(Date:7/23/2014)... 2014 "I wanted a better way to ... my blood sugar, blood pressure and pulse rate," said an ... have to carry along a bunch of different devices, so ... developed the Master III to make it easier to monitor ... convenient unit. The accessory enables the user to have more ...
(Date:7/23/2014)... shown that some high-profile athletes who suffered repeated blows ... clumps in their brains. Those clumps suggest the athletes ... scientists are working on tests that might be able ... an article in Chemical & Engineering News (C&EN) ... Society. , In the article, Lauren Wolf, a senior ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 6Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2
... who regularly complain of fatigue can increase their energy levels ... by engaging in regular, low intensity exercise, according to a ... that a quick workout will leave us worn out ... Puetz, who recently completed his doctorate at UGA and is ...
... Launch New Accreditation Program This Spring, LOVELAND, ... (PHII), a non-profit 501(c)(3) organization that promotes,credible, transparent, ... announces the election of Joel V.,Brill, MD; Garry ... to the PHII,Board of Directors. They will join ...
... Philadelphia, PA, February 28, 2008 There is a ... adults diagnosed with schizophrenia. However, there is a ... and adolescents with schizophrenia. Although the U.S. Food ... of aripiprazole and risperidone for adolescents with schizophrenia, few ...
... of dermatologist endorsed moisturizers, MEMPHIS, Tenn., Feb. ... full line of dermatologist endorsed moisturizers especially,created to ... launching its 2008,"Prepare to Unveil Yourself" initiative with ... skin. Four Theraplex(R) solutions:,HydroLotion, ClearLotion, Emollient, and Theraplex ...
... (NEWARK, N.J., Feb. 28, 2008) New Jersey State ... Administration Research Education) Award for Excellence in Research to ... Flynn, assistant professor at the College of Nursing at ... honored with three other C.A.R.E. award recipients during the ...
... Feb. 28 Boston Scientific,Corporation (NYSE: ... implants of its,COGNIS(TM) cardiac resynchronization therapy defibrillator ... began,performing implants earlier this week. Forty implants ... countries., When choosing a high-energy device, ...
Cached Medicine News:Health News:Low-intensity exercise reduces fatigue symptoms by 65 percent, study finds 2Health News:Population Health Impact Institute Announces New Board Members 2Health News:Comparison of antipsychotic treatments in adolescents with schizophrenia 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4Health News:Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death 2Health News:Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death 3Health News:Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: